Report / Paper metadata
Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data.
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Limits
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Kind
- Paper metadata